Patents Examined by Daniel R Carcanague
  • Patent number: 11912705
    Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: February 27, 2024
    Assignee: The Corporation of Mercer University
    Inventors: Clinton E. Canal, Nader Moniri, Yiming Chen
  • Patent number: 11912713
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: February 27, 2024
    Assignee: Trevena, Inc.
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C. K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero
  • Patent number: 11912707
    Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: February 27, 2024
    Inventors: Andrew Kruegel, Dalibor Sames, Madalee G. Wulf, Jonathan A. Javitch
  • Patent number: 11912673
    Abstract: A process for preparing a tetra-substituted aminobiphenol macrocyclic ligand having the structure (I), including the step of treating a precursor compound having the structure (II) with a compound having the structure R6-L where L is a leaving group (hereafter compound (III)) in the presence of a base.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: February 27, 2024
    Assignee: Econic Technologies Ltd.
    Inventors: Michael Kember, Anthony Chartoire, Anthea Blackburn, Samuel Drane
  • Patent number: 11905285
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: February 20, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • Patent number: 11898083
    Abstract: The present disclosure relates to an azobenzene-graphene metal coordination solar photothermal energy storage material based on metal coordination bonds and a preparation method thereof. The method comprises the following steps: preparing reduced graphene oxide; preparing an azobenzene-graphene material; and preparing an azobenzene-graphene metal coordination solar photothermal energy storage material: dispersing the prepared azobenzene-graphene material in DMF, dissolving a certain amount of metal compound in DMF, adding the DMF solution of the metal compound into the DMF solution of the azobenzene-graphene, taking out the precipitate, washing off metal ions which do not participate in coordination, and drying the obtained product to obtain the azobenzene-graphene metal coordination solar photothermal energy storage material.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: February 13, 2024
    Inventors: Yiyu Feng, Hui Wang, Wei Feng, Huitao Yu
  • Patent number: 11897873
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: February 13, 2024
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Patent number: 11891404
    Abstract: The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: February 6, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Sven Wittrock, David McKinney, Michael H. Serrano-Wu, Chris Lemke, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick Ryan McCarren, Rebecca Ann Harvey
  • Patent number: 11884678
    Abstract: The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: January 30, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Motoshi Yamauchi, Keiji Nakayama
  • Patent number: 11884682
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: January 30, 2024
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • Patent number: 11884629
    Abstract: Provided are embodiments of para-substituted 1,1-dialkyl-4-phenylpiperazin-1-ium iodides advantageous for modulating inflammation that have been synthesized and their electrophysiology activities for ?9, ?9?10, and ?7 nAChRs compared. The para position contained alkyl or aryl amides, or heterocyclic isosteres for the amide, and the alkyl groups were varied at the ammonium piperazine nitrogen to see if compensatory changes in size at this position of the molecule impacted function. The compounds were characterized with two-electrode voltage-clamp measurements on Xenopus oocytes expressing nAChRs. General, the compounds were more potent for ?9-containing receptors than for ?7, and the majority were either full or strong partial agonists for ?9-containing nAChR.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: January 30, 2024
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Nicole Alana Horenstein, Roger Lee Papke, Hina Andleeb
  • Patent number: 11884638
    Abstract: The present disclosure relates to a novel compound or a salt thereof, a composition for detecting cysteine, a fluorescent probe, and a composition for diagnosing cancer, which contain the same, a method for detecting cysteine, a method for providing information for diagnosing cancer, and a method for producing the novel compound. According to the present disclosure, there may be provided a method of synthesizing and purifying a fluorescent probe for cysteine detection and applying the same to diagnose cervical cancer by detecting cysteine in human urine.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: January 30, 2024
    Inventors: Do Kyoung Kim, Chang Wook Jeong, Jong Min An
  • Patent number: 11883381
    Abstract: Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, David Rogawski, Dmitry Borkin, Szymon Klossowski, Zhuang Jin, Deanna Montgomery, Jing Deng, Marta Krotoska, Hao Li
  • Patent number: 11883386
    Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: January 30, 2024
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D Greis, Angelique Sun Boyer, Namal C. Warshakoon
  • Patent number: 11884649
    Abstract: Disclosed herein, inter alia, are compounds for inhibiting IRE1? and uses thereof.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 30, 2024
    Assignees: The Regents of the University of California, University of Washington
    Inventors: Feroz R. Papa, Bradley J. Backes, Dustin J. Maly
  • Patent number: 11885818
    Abstract: The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: January 30, 2024
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Hans-Peter Josel, Uwe Kobold, Christoph Seidel, Martin Rempt, Andreas Leinenbach, Giuseppe Prencipe, Silvia Baecher, Simon Ferdinand Loibl, Anna-Skrollan Geiermann, Jelena Milic, Nicole Pirkl
  • Patent number: 11878020
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • Patent number: 11872219
    Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 16, 2024
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Barton Harley Manning
  • Patent number: 11866433
    Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: January 9, 2024
    Inventors: Chunli Shen, Chengde Wu, Shenglin Chen, Shuhui Chen, Xiquan Zhang, Xin Tian
  • Patent number: 11858945
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: January 2, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or